Biogen is a leading biotechnology company focused on developing therapies for neurological and neurodegenerative diseases. On May 27, 2026, RBC Capital analyst Brian Abrahams raised the stock price target for Biogen to $227.00. This new target suggests a potential 17.57% increase from the stock's price of $193.08 at the time of the announcement, offering a positive Biogen stock forecast.
This optimistic outlook comes despite recent setbacks in the company's drug pipeline. Biogen and its partner, Denali Therapeutics (NASDAQ: DNLI), announced they will stop developing their Parkinson's drug, BIIB122. As highlighted by Reuters, this decision follows the drug's failure to meet its main goal in a mid-to-late stage study, impacting biopharma investment analysis.
The company also faced a challenge with its experimental Alzheimer's treatment, diranersen. As noted by MarketBeat, the drug's Phase 2 study missed its primary goal. These trial failures are significant events, as new drug approvals are critical for biotechnology firms and are overseen by bodies like the U.S. Food & Drug Administration (FDA).
Despite these trial misses, the analyst's positive view may be supported by other company activities. Biogen had a strong first-quarter earnings report. It also plans to acquire Apellis Pharmaceuticals for $41.00 per share, which will add two commercialized drugs for rare diseases and immunology to its portfolio, strengthening Biogen's market position and future stock performance.
Currently, Biogen stock trades at $193.08, with a market capitalization of about $28.51 billion. The stock has seen a 52-week trading range between $121.05 and $205.97. Market capitalization is the total value of a company's shares and is found by multiplying the stock price by the number of shares.
